<DOC>
	<DOCNO>NCT01462643</DOCNO>
	<brief_summary>The aim exploratory study compare dose related effect LAS41004 formulation non-occlusive PPT .</brief_summary>
	<brief_title>Efficacy Tolerability LAS41004 Formulations Non-occlusive Psoriasis Plaque Test</brief_title>
	<detailed_description>Going non-occlusive application design allow draw practical conclusion similar real treatment situation ( compare occlude design maximise effect )</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>18 75 year age Caucasian men woman Suffering mild moderate plaque psoriasis least 6 month duration amenable local therapy With least one stable psoriatic plaque area sufficient product application meeting follow criterion : 1. locate trunk and/or extremity ( plaque locate head , palm , sole foot , intertriginous genitoanal area suitable ) 2 . Where one plaque use , plaque comparable , least `` 2 '' score scaling , erythema induration . 3 . No 3 point difference total score ( sum score scale , erythema induration ) 4 . Negative urine pregnancy test ( female patient child bear potential ) In case woman childbearing potential , use reliable method contraception result low failure rate i.e . le 1 % per year ( eg contraceptive implant injectables , combine oral contraceptive , intrauterine device , sexual abstinence vasectomize partner ) Patients need systemic treatment psoriasis Severe form psoriasis form psoriasis chronic plaque psoriasis , include : guttate erythroderma exfoliative pustular psoriasis psoriatic arthritis Changes expression psoriasis within last 6 week prior screen Intensive UV light exposure within two week begin test well study four week end study test area Systemic treatment ( see table ) : Corticosteroids , antibiotic 4 week prior study day 1 conduct study Retinoids Ciclosporin Methotrexate Fumaric acid ester 3 month prior study day 1 conduct study Antiinflammatory substance , NSAIDs 2 week prior study day 1 conduct study Biologics 6 month prior study day 1 conduct study Planned initiation , change concomitant medication could affect Psoriasis ( e.g . beta blocker , antimalaria drug , lithium ) 8 week study start study Topical treatment body region corticosteroids immunosuppressant 20 % body surface area treat Treatment nonmarketed drug substance within 4 week prior study day 1 Topical treatment test area without adequate time washout Diseases : Skin infection cause bacteria , virus fungi , include limited tuberculosis , syphilis varicella zoster infection Parasitic infection Rosacea , perioral dermatitis test area Moderate severe illness within last two week first exposure Other know infectious disease ( e.g . hepatitis AIDS ) Other skin disease may confound evaluation psoriasis Known hypersensitivity ingredient study drug , Known calcium metabolism disorder History malignancy organ system Severe impairment liver kidney function Pregnancy lactation Participation clinical trial within last 30 day prior start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Psoriasis Plaque Test</keyword>
	<keyword>topical</keyword>
	<keyword>ointment</keyword>
</DOC>